NASDAQ:ACB - Nasdaq - CA05156X8504 - Common Stock - Currency: USD
AURORA CANNABIS INC
NASDAQ:ACB (2/5/2025, 2:47:03 PM)
5.4499
+1.77 (+48.1%)
The current stock price of ACB is 5.4499 USD. In the past month the price decreased by -21.7%. In the past year, price decreased by -15.27%.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
ACB earnings call for the period ending December 31, 2024.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 83.04 | 801.72B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 29.21 | 382.65B | ||
JNJ | JOHNSON & JOHNSON | 15.44 | 371.30B | ||
MRK | MERCK & CO. INC. | 11.86 | 229.21B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.89 | 219.92B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.61 | 219.91B | ||
PFE | PFIZER INC | 8.52 | 150.23B | ||
SNY | SANOFI-ADR | 13.57 | 134.72B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 51.43 | 122.04B | ||
ZTS | ZOETIS INC | 30.53 | 79.33B | ||
GSK | GSK PLC-SPON ADR | 9.14 | 77.20B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.16 | 42.48B |
Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. The company is headquartered in Leduc, Alberta and currently employs 1,073 full-time employees. The company went IPO on 2007-09-26. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants in North America. Its segments include Canadian Cannabis and Plant Propagation. The firm's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. The company also has a controlling interest in Bevo Farms Ltd., North America's supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
AURORA CANNABIS INC
2207 90B Street Sw
Leduc ALBERTA T5J 1Y6 CA
CEO: Terry Booth
Employees: 1073
Company Website: https://www.auroramj.com/
Investor Relations: https://www.auroramj.com/investors/
Phone: 16043625207
The current stock price of ACB is 5.4499 USD.
The exchange symbol of AURORA CANNABIS INC is ACB and it is listed on the Nasdaq exchange.
ACB stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ACB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ACB.
ACB does not pay a dividend.
ACB will report earnings on 2025-02-05, before the market open.
ACB does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
The outstanding short interest for ACB is 8.94% of its float.
ChartMill assigns a fundamental rating of 3 / 10 to ACB. ACB may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ACB reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS decreased by 27.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -5.4% | ||
ROE | -8.04% | ||
Debt/Equity | 0.08 |
ChartMill assigns a Buy % Consensus number of 72% to ACB. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -9.1% and a revenue growth 17.55% for ACB